Table 1:

Clinical characteristics of patients with ovarian low-grade serous tumors with histologic transformation

Characteristic	Entire cohort (n=40) No. of patients (%)	LGS-HT-Sync (n=30) No. of patients (%)	LGS-HT-Metac (n=10) No. of patients (%)
Age	56 (26–78)	56 (29–78)	58 (26–72)
Stage
I/II	7 (17.5%)	4 (13.3%)	3 (30.0%)
III/IV	33 (82.5%)	26 (86.7%)	7 (70.0%)
Primary treatment
Primary debulking surgery	30 (75.0%)	22 (73.3%)	8 (80.0%)
NACT	10 (25.0%)	8 (26.7%)	2 (20.0%)
Residual disease after surgery†
Complete gross resection	14 (46.7%)	7 (31.8%)	7 (87.5%)
Optimal debulking	14 (46.7%)	13 (59.9%)	1 (12.5%)
Suboptimal debulking	2 (6.7%)	2 (9.1%)	0 (0%)
Post-operative Treatment
Adjuvant chemotherapy	38 (95%)	30 (100%)	8 (80.0%)
Maintenance therapy
Endocrine therapy	6 (15.0%)	4 (13.3%)	2 (20.0%)
Bevacizumab	7 (17.5%)	7 (23.3%)	0 (0%)
PARP inhibitor	2 (5.0%)	2 (6.7%)	0 (0%)

LGS-HT – low-grade serous tumors with histologic transformation (S - synchronous low-grade and higher-grade components; M – metachronous low-grade and higher-grade components); NACT – neoadjuvant chemotherapy.

^†Data for residual disease after surgery were missing for 10 patients.